SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...
This article is based on a poster originally authored by Ariane Jonetz-Mentzel et al. In biopharmaceutical laboratories, there is an increasing demand for label-free, high-throughput screening based ...
Conventional high throughput screening for clinical candidates cannot evaluate over 99% of commercially available molecules, thereby restricting the accessible chemical search space for therapeutic ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...
Fragment-based drug design (FBDD) has led to a revolution in contemporary drug discovery, facilitating a bottom-up approach to the identification and evolution of bioactive small molecules into viable ...
SCIEX launched the Echo ® MS+ system at SLAS 2024. According to the company, the system couples proprietary acoustic ejection mass spectrometry technology and open port interface (OPI) sampling with ...
The SCIEX Echo MS+ and ZenoTOF 8600 systems redefine screening with one-second acoustic sampling and 10x sensitivity. By removing LC bottlenecks, this label-free platform accelerates drug discovery ...
To address the demand for rapid, highly specific therapeutic candidates, Creative Biolabs has optimized its comprehensive suite of antibody discovery platforms.
Organoids, assembloids, and organ-on-a-chip technologies represent transformative advances in the fields of drug discovery, precision medicine, and ...
Optimized chemistry enables direct synthesis of up to 500 bp double stranded fragments “Using our chemical synthesis platform we are able to directly synthesize Twist Multiplexed Gene Fragments as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results